FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 1 of 3

ATTORNEY DOCKET No.	SERIAL NO.
6102-000013/US/NP	10/585,609
APPLICANT	
Scheller, D.	
FILING DATE	GROUP
March 12, 2007	1614

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
		2003/0026830	Feb 6, 2003	Lautertback, et al.	424/449	May 7, 2002
		2003/0027793	Feb 6, 2003	Lautertback, et al.	514/63	May 7, 2002
		2003/0166709	Sep 4, 2003	Rimpler, et al.	514/447	Feb 11, 2003
		2004/0034083	Feb 19, 2004	Stephenson et al.	514/406	Apr 14, 2003
		2004/0048779	Mar 11, 2004	Schollmayer	514/2	May 2, 2003
	T	2004/0081683	Apr 29, 2004	Schacht, et al.	424/449	Jul 28, 2003
		2004/0116537	Jun 17, 2004	Li, et al.	514/663	Nov 17, 2003
		2004/0137045	Jul 15, 2004	Breitenbach, et al.	424/449	Feb 6, 2004
		2004/0209861	Oct 21, 2004	Benavides, et al.	514/210.01	Feb 25, 2004
	Ĭ	2005/0033065	Feb 10, 2005	Mueller, et al.	549/74	Sep 7, 2004
		2005/0079206	Apr 14, 2005	Schacht, et al.	424/449	Jul 22, 2003
		2005/0175678	Aug 11, 2005	Breitenbach	424/448	Dec 6, 2004
		2005/0260254	Nov 24, 2005	Breitenbach, et al.	424/449	Jan 28, 2005
		2006/0263419	Nov 23, 2006	Wolff	424/448	Sep 29, 2005
		2007/0072917	Mar 29, 2007	Scheller, et al.	514/357	Jan 25, 2006
		2007/0093546	Apr 26, 2007	Scheller, et al.	514/447	Jan 25, 2006
	1	2007/0191308	Aug 16, 2007	Kramer	514/60	Aug 15, 2005
		2007/0191470	Aug 16, 2007	Scheller	514/438	Sep 22, 2006
		2007/0197480	Aug 23, 2007	Scheller, et al.	514/114	Feb 6, 2007
		2008/0008748	Jan 10, 2008	Beyreuther, et al.	424/449	Jun 19, 2007
		2008/0138389	Jun 12, 2008	Muller, et al.	424/448	Oct 31, 2007
		2008/0274061	Nov 6, 2008	Schollmayer, et al.	424/45	May 2, 2008
		2009/0143460	Jun 4, 2009	Wolff, et al.	514/438	Nov 26, 2008
		5,177,112	Jan 5, 1993	Horn	514/65	Sep 10, 1991
		5,382,596	Jan 17, 1995	Sleevi, et al.	514/459	Aug 5, 1993
		6,372,920	Aug 16, 2002	Minaskanian, et al.	549/75	Nov 16, 2000
		6,884,434	Apr 26, 2005	Muller, et al.	424/487	Nov 28, 2000

Examiner: Date Considered:

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 2 of 3

ATTORNEY DOCKET NO.	SERIAL NO.	
6102-000013/US/NP	10/585,609	
APPLICANT		
Scheller, D.		
FILING DATE	GROUP	
March 12, 2007	1614	

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
		7,309,497	Dec 18, 2007	Rimpler, et al.	424/422	Feb 11, 2003
		7,413,747	Aug 19, 2008	Mueller, et al.	424/448	Oct 31, 2007

OTHER DOCUMENTS			
Ref. Desig.	Examiner's Initials		
		Den Daas, et al. (1991) "Orally active carbamate prodrugs of the selective dopamine agonist N-0437: In-vivo activities in the 6-OHDA turning model and In-vitro activities." J. Pharm. Pharmacol. 43:11-16	
		Gerlach, et al. (2003) "Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease." Neurotoxicity Research 5(1):43-51	
		Hughes, et al. (1992) "Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases." Journal of Neurology, Neurosurgery, and Psychiatry 55:181-184	
		Kihara, et al. (2002) "Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase casade." J. Neurosci. Res. 70:274-282	
		Mark (2001) " Lumping and splitting the Parkinson plus syndromes." Movement Disorders 19(3):607-627	
		Martinez-Martin, et al. (1994) "Unified Parkinson's disease rating scale characteristics and structure." Movement Disorders 9(1):76-83	
		McKay, et al. (2008) "Will stem cell biology generate new therapies for Parkinson's disease?" Neuron 58:659-661	
		Nair, et al. (2003) "Activation of phosphoinositide 3-kinase by D₂ receptor prevents apoptosis in dopaminergic cell lines." Biochem. J. 373:25-32	
		Oertel, et al. (2003) "New aspects in the treatment of Parkinson's disease." Akt Neurol 30(Suppl 2):S263-265	
		Oertel, et al. (2003) "New aspects in the treatment of Parkinson's disease." Akt Neurol 30(Suppl 2):S263-265 (English Translation)	
		R & D Focus Drugs News, 20 Aug 2001, "Drug delivery system, transdermal rotigotine Schwartz clinical data (treatment of Parkinson's disease." IMS World Pulications Ltd. ISSN:1350-1135	
		Rascol, et al. (2002) "Treatment interventions for Parkinson's disease: an evidence based assessment." Lancet 359:1589-1598	
		Schapira (2002) "Neuroprotection and dopamine agonists." Neurology 58(Suppl 1):S9-S18	

Examiner:	Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 3 of 3

ATTORNEY DOCKET No.	SERIAL NO.
6102-000013/US/NP	10/585,609
APPLICANT	
Scheller, D.	
FILING DATE	GROUP
March 12, 2007	1614

OTHER DOCUMENTS			
Ref. Desig.	Examiner's Initials		
		Scheller, et al. (2007) "Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease." Experimental Neurology 203:415-422	
		Scheller, et al. (2008) "Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease." Neuroscience Letters 432:30-34	
		Takashima, et al. (1999) "Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D ₂ receptors." Exp. Neurol. 159:98-104	
		Thomas, et al. (2007) "Dopa-responsive pseudo-orthostatic tremor in Parkinsonism." Movement Disorders 22(11):1652-1656	
		Van der Weide, et al. (1988) "The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors." Eur J Pharmacol 146:319-326	

Examiner:	Date Considered:	